Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE)

Lupus

Volumn 18, Issue 4, 2009, Pages 361-363

  Rizos, Timolaos ^a   Siegelin, M ^a   Hahnel S ^a   Storch Hagenlocher, B ^a   Hug, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain biopsy; Neurological ICU; Neuropsychiatric systemic lupus erythematosus; Systemic lupus erythematosus; Vasculitis

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M; MEPREDNISONE;

ACUTE DISEASE; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BRAIN BIOPSY; BRAIN VASCULITIS; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; MENINGOENCEPHALITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOPSY; BRAIN; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; METHYLPREDNISOLONE; MIDDLE AGED; PROGNOSIS;

EID: 62749120259     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308097448     Document Type: Article

References (16)

1. Mitchell I Webb M Hughes R Stewart J. Cerebral lupus. Lancet 1994; 343: 579-582.
2. Jongen PJ Boerbooms AM Lamers KL Raes BC Vierwindan G. Diffuse CNS involvement in systemic lupus erythematosus: Intrathecal synthesis of the 4th component of complement. Neurology 1990; 40: 1593-1596.
3. Fady G Joseph G Lammie A Neil J. Scolding. CNS lupus: A study of 41 patients. Neurology 2007; 69: 644-654.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
5. Teasdale G Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2: 81-84.
6. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957; 5: 200-215.
7. Lindley RI Waddell F Livingstone M. Can simple questions assess outcomes after stroke. Cerebrovasc Dis 1994; 4: 314-324.
8. ACR ad hoc committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
9. Tan EM Feltkamp TE Smolen JS. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40: 1601-1611.
10. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
11. Afeltra A Garzia P Mitterhofer AP. Neuropsychiatric lupus syndromes. Relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-110.
12. Hanly JG Walsh NMG Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732-741.
13. Hess DC. Cerebral lupus vasculopathy. Mechanisms and clinical relevance. Ann N Y Acad Sci 1997; 823: 154-168.
14. Johnson RT Richardson EP. The neurological manifestations of systemic lupus erythematosus. A clinical-pathological study of 24 cases and review of the literature. Medicine 1968; 47: 337-369.
15. Jonson A Bengtsson A Nived O Ryberg B Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology 2002; 41: 1308-1312.
16. Tokano Y Morimoto S Amano H. The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus. Mod Rheumatol 2005; 15: 275-282.